title: Combination of gemcitabine and cisplatin as first-line therapy in advanced non-small-cell lung cancer.
abstract: OBJECTIVE
  The prognosis of patients with advanced non-small-cell lung cancer (NSCLC) is extremely poor. Many prospective randomized trials on patients with advanced NSCLC suggested systemic chemotherapy improves both the survival and quality of life. A phase II trial was conducted to evaluate the efficacy and safety profile of the combination chemotherapy of gemcitabine and cisplatin in advanced NSCLC.
  
  
  METHODS
  Forty-four patients with locally advanced or metastatic NSCLC were enrolled. The patients received a cisplatin, 75 mg/m(2), infusion over 30 minutes on days 1, followed by a gemcitabine, 1,250 mg/m(2), infusion over 30 minutes on days 1 and 8 every 3 weeks.
  
  
  RESULTS
  The median age of the patients was 64 years (range: 27 approximately 75). Forty-one patients were assessable for response and toxicity analyses. The overall response rate was 53.6%, but with no complete remissions. The median time to progression was 5.6 months (range: 1 approximately 15.4). The median survival was 14.2 months (95% confidence interval (CI), 13.8 approximately 22.5). A total of 179 cycles were administered, with a median of 4 cycles of chemotherapy, ranging from 2 to 9 cycles. The most common hematological toxicities were NCI grades 3/4 neutropenia (24%) and thrombocytopenia (7.8%). The most common non-hematological toxicity was fatigue (42.4%). There were no life-threatening toxicity or treatment related mortalities. The median duration of follow up was 9.4 months, ranging from 1.6 to 30.3 months.
  
  
  CONCLUSIONS
  In this trial, the combination of gemcitabine and cisplatin showed significant activity, with acceptable and manageable toxicities as a first-line regimen for patients with advanced NSCLC.
authors.affiliation: Department of Internal Medicine, Soon Chun Hyang University College of Medicine, Seoul, Korea.
authors.forename: Nam-Su
authors.initials: NS
authors.lastname: Lee
authors.forename: Jae-Ho
authors.initials: JH
authors.lastname: Byun
authors.forename: Sang-Byung
authors.initials: SB
authors.lastname: Bae
authors.forename: Chan-Kyu
authors.initials: CK
authors.lastname: Kim
authors.forename: Kyu-Taeg
authors.initials: KT
authors.lastname: Lee
authors.forename: Sung-Kyu
authors.initials: SK
authors.lastname: Park
authors.forename: Jong-Ho
authors.initials: JH
authors.lastname: Won
authors.forename: Dae-Sik
authors.initials: DS
authors.lastname: Hong
authors.forename: Hee-Sook
authors.initials: HS
authors.lastname: Park
references.citation: J Clin Oncol. 1993 Oct;11(10):1866-72
references.pmid: 8410111
references.citation: Semin Oncol. 1994 Jun;21(3 Suppl 6):49-59
references.pmid: 8052874
references.citation: Ann Oncol. 2000 Oct;11(10):1295-300
references.pmid: 11106119
references.citation: Lung Cancer. 2002 Jan;35(1):73-9
references.pmid: 11750716
references.citation: J Clin Oncol. 1997 Jan;15(1):297-303
references.pmid: 8996156
references.citation: Anticancer Res. 2002 Sep-Oct;22(5):3039-43
references.pmid: 12530039
references.citation: N Engl J Med. 2002 Jan 10;346(2):92-8
references.pmid: 11784875
references.citation: J Clin Oncol. 1997 Feb;15(2):744-9
references.pmid: 9053500
references.citation: J Clin Oncol. 2003 Nov 1;21(21):3909-17
references.pmid: 14581415
references.citation: Jpn J Clin Oncol. 2002 Feb;32(2):43-7
references.pmid: 11948227
references.citation: Anticancer Drugs. 1995 Dec;6 Suppl 6:19-25
references.pmid: 8718421
references.citation: Chest. 1991 Jun;99(6):1326-8
references.pmid: 1645242
references.citation: Clin Cancer Res. 1998 May;4(5):1087-100
references.pmid: 9607565
references.citation: Anticancer Res. 2002 Sep-Oct;22(5):3087-92
references.pmid: 12530048
references.citation: N Engl J Med. 1992 Nov 12;327(20):1434-41
references.pmid: 1328881
references.citation: Cancer Nurs. 1999 Apr;22(2):176-83
references.pmid: 10217035
references.citation: Eur J Cancer. 1996 Feb;32A(2):243-8
references.pmid: 8664035
references.citation: Chest. 1994 Sep;106(3):861-5
references.pmid: 7521815
references.citation: J Clin Oncol. 1999 Oct;17(10):3188-94
references.pmid: 10506617
references.citation: BMJ. 1995 Oct 7;311(7010):899-909
references.pmid: 7580546